Eduard Vrdoljak

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Luca Gianni, Urania Dafni, Richard D. Gelber et al. · The Lancet Oncology · 2011 · 611 citations

Breast Oncology, Oncology, Adjuvant Chemotherapy +5

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

Martin Gore, Cezary Szczylik, Camillo Porta et al. · The Lancet Oncology · 2009 · 590 citations

Urology, Oncology, Metastatic Renal-cell Carcinoma +8

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

Martin Gore, Cezary Szczylik, Camillo Porta et al. · British Journal of Cancer · 2015 · 190 citations · Full text

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Gϋnter von Minckwitz, Fabio Puglisi, Javier Cortés et al. · The Lancet Oncology · 2014 · 145 citations

Metastatic Breast Cancer, Chemotherapy Versus Chemotherapy, Breast Oncology +7

Microsatelite GT polymorphism in the toll‐like receptor 2 is associated with colorectal cancer

Tihana Boraska Jelavić, Marin Barišić, Irena Drmić Hofman et al. · Clinical Genetics · 2006 · 102 citations